Navigation Links
WuXi PharmaTech Announces Second-Quarter 2009 Results
Date:8/11/2009

Weighted average ADS outstanding - basic (Non-GAAP) 67,944,436 62,588,246 67,469,104 62,241,856 Weighted average ADS outstanding - diluted (Non-GAAP) 73,152,798 72,949,790 73,356,170 72,731,304 WUXI PHARMATECH (CAYMAN) INC. REVENUE BREAKDOWN (in thousands of U.S. dollars) Three Months Ended Six Months Ended June 30, June 30, 2009 2008 % 2009 2008 % Net revenues: China-based Laboratory Services 44,810 35,564 26% 86,458 67,983 27% U.S.-based Laboratory Services* 16,679 15,962 4% 31,626 26,059 21% Subtotal 61,489 51,526 19% 118,084 94,042 26% China-based Manufacturing Services 5,464 17,556 (69%) 8,017 31,208 (74%) Total net revenues 66,953 69,082 (3%)126,101 125,250 1% * Only five months of revenues (February to June 2008) were included in 2008 for U.S.-based Laboratory Services because that business was acquired on January 31, 2008.

Conference Call

WuXi PharmaTech senior management will host a conference call at 8:00 am (Eastern) / 5:00 am (Pacific) / 8:00 pm (Beijing/Shanghai/Hong Kong) on Wednesday, August 12, 2009, to discuss its second-quarter 2009 financial results and future prospects. The conference call may be accessed by calling:

    United States: 1-866-519-4004
    China (Landline): 800-819-0121
    China (Mobile): 400-620-8038
    Hong Kong: 800-933-053
    United Kingdom: 0-808-234-6646
    International: +65-6735-7955
    Conference ID: 96870349
    Web PIN: 8656

A telephone replay will be avai
'/>"/>

SOURCE WuXi PharmaTech (Cayman) Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related biology technology :

1. WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2009 Annual General Meeting
2. WuXi PharmaTech Schedules Second-Quarter 2009 Earnings Release
3. WuXi PharmaTech Receives Award from BASF
4. WuXi PharmaTech Named a Top Ten Chinese Outsourcing Enterprise
5. WuXi PharmaTech Appoints Felix Hsu as Senior Vice President of U.S. Operations
6. WuXi PharmaTech Appoints Wei-Min Chang as Vice President of Operations and General Manager of SynTheAll Manufacturing Facility, Eric Gu as Vice President of Business Development for Manufacturing Services
7. WuXi PharmaTech to Present at Third Annual Jefferies Healthcare Conference
8. WuXi PharmaTech Schedules First-Quarter 2009 Earnings Release
9. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
10. WuXi PharmaTech Announces Fourth-Quarter and Full-Year 2008 Results
11. The Fitzsimons Redevelopment Authority Selects Pharmatech Oncology as Preferred Vendor
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014  CorMedix Inc. (NYSE MKT: CRMD), ... therapeutic products for the prevention and treatment of ... notice on July 18, 2014 from the NYSE ... the CorMedix plan to regain compliance with continued ... the NYSE-MKT is continuing the Company,s listing and ...
(Date:7/24/2014)... Mich. , July 24, 2014  Neogen Corporation ... that future forecasts of its potential revenue from new ... call to investors and analysts on July 22, 2014, ... by analysts regarding this research. "It was ... questions about the potential of a new type of ...
(Date:7/24/2014)... 24, 2014 The first part of ... in First in Human Studies” will cover comprehensive clinical ... decisions. , With increasing R&D costs and declining industry ... to maximize the knowledge collected in early Phase I/IIa ... success in late stage development. , Next, the presenters ...
(Date:7/24/2014)... , July 24, 2014   Cypher Genomics, ... the appointment of Adam Simpson as ... provides rapid and comprehensive annotation and interpretation of ... reporting. "Cypher,s technology has the potential ... by enhancing diagnostic accuracy, optimizing therapeutic approaches and ...
Breaking Biology Technology:CorMedix, Inc. Granted Extension of NYSE-MKT Listing 2CorMedix, Inc. Granted Extension of NYSE-MKT Listing 3Neogen comments on SenesTech 2Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 2Cypher Genomics Announces the Appointment of Adam Simpson as President and COO to Advance Transformative Genome Interpretation Technology 3
... ORANGE, N.J., Oct. 18, 2011 Kessler Foundation announced ... Research Center as Director of the Human Performance and ... 2012. "The addition of Dr. Yue is ... physical and cognitive research aimed at improving rehabilitation for ...
... 18, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical Inc. (NYSE ... "Company"), a developer, manufacturer and distributor of botanical products, ... announced that the board increased the number of directors ... annual board meeting and appointed Mr. Zack Zibing Pan ...
... Oct. 18, 2011 Immune Design Corp. (IDC) announced ... the company as its new Chief Business Officer.  In ... years of pharmaceutical and biotechnology industry experience to lead ... advancing pipeline of novel therapeutic vaccines and immunotherapies for ...
Cached Biology Technology:Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory 2Kessler Foundation Appoints New Director of Human Performance and Engineering Laboratory 3China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee 2China Botanic Appoints Zack Zibing Pan as an Independent Director and Chairman of its Audit Committee 3Immune Design Corp. Appoints Guy F. Cipriani as Chief Business Officer 2
(Date:7/24/2014)... of 3.5 billion years of evolutionary trial and error, ... it may be reaching a tipping point. , In ... data published in Science , an international team ... animals is contributing to what appears to be the ... event. , Since 1500, more than 320 terrestrial vertebrates ...
(Date:7/24/2014)... own microbial terroir, meaning the microbial populations found on ... product, creating the final flavor according to research published ... Environmental Microbiology . This is the first time investigators ... , Many sake makers inoculate with both bacteria ... the University of California, Davis, but he and his ...
(Date:7/24/2014)... 2014(BRONX, NY)Researchers at Albert Einstein College of Medicine ... The Michael J. Fox Foundation for Parkinson,s Research to ... Parkinson,s disease. This drug discovery project will test chemical ... of developing a drug that acts on an underlying ... for Parkinson,s help many people manage their symptoms, we ...
Breaking Biology News(10 mins):Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3The microbes make the sake brewery 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 2Albert Einstein College of Medicine receives grant from the Michael J. Fox Foundation to fund drug discovery project targeting Parkinson's 3
... there is a serious influenza outbreak will do little to ... findings of a study conducted at the UK Health Protection ... Sometimes a new type of influeza virus appears that causes ... case for flu. This happened, for example, in 1918, when ...
... defined the collective genome of the human gut, or colon. ... make up a motley "microbiome" that allows humans to digest ... fiber. , In a study published in the June ... for Genomic Research (TIGR) and their colleagues describe and analyze ...
... spend $21 billion for HIV/AIDS research, treatment, prevention, and ... study published in the July 1 issue of The ... it is--and more so than previously thought. , The ... , MD, MSc and colleagues at Massachusetts General Hospital ...
Cached Biology News:Air travel and pandemic flu 2Gut reaction: Researchers define the colon's genome 2Gut reaction: Researchers define the colon's genome 3New study calculates millions of years saved in lives of AIDS patients 2
... TOPO Cloning Kits for Sequencing allow 5-minute cloning ... contain TOPO Cloning vectors with primer sites located ... PCR product insertion site. This minimizes the amount ... before reaching the sequence of your insert.vectors are ...
Blot Paper 7 x 8.5cm semi-dry western blots (order number RB-400)...
The product contains 10 ml Dynabeads Epoxy (4.5 m). Supplied at 4 x 10 8 beads/ml...
Request Info...
Biology Products: